Karyopharm announces dosing of first patients in two new company-sponsored clinical studies in melanoma and myelofibrosis

Newton, mass., july 28, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored phase 2 and 1/2 clinical studies evaluating xpovio® (selinexor), the company's first-in-class, oral selective inhibitor of nuclear export (sine) compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naÏve myelofibrosis.
KPTI Ratings Summary
KPTI Quant Ranking